Source: Clinical Lab Products

SeraCare: Tumor Mutational Burden Reference Materials

SeraCare has released the first genomic DNA and formalin-fixed, paraffin-embedded reference materials for the measurement of tumor mutational burden via next-generation sequencing assays.

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
100-250
Michael Sweatt's photo - General Manager of SeraCare

General Manager

Michael Sweatt

CEO Approval Rating

82/100

Read more